Possible Role of Granulocyte Colony-Stimulating Factor in Increased Serum Soluble Interleukin-2 Receptor-α Levels After Allogeneic Bone Marrow Transplantation

References

• Uchiyama T., Brode S., Wdldmann T. A. A monoclonal antibody (anti‐Tac) reactive with activated and functionally mature human T cells. J Immunol. 1981; 126: 1393–1403
   PubMed Web of Science ®Google Scholar
• Leonard W. J., Depper J. W., Uchiyama T., Smith K. A., Waldman T. A., Greene W. A monoclonal antibody that appears to recognize the receptor for human T‐cell growth factor. Partial characterization of the receptor. Nature 1982; 300: 267–269
   PubMed Web of Science ®Google Scholar
• Lowenthal J. W., Greene W. C. Contrasting inter‐leukin 2 binding properties of the α (p55) and β (p70) proteins subunits of the high‐affinity interleukin 2 receptor. J Exp Med. 1987; 166: 1156–1161
   PubMed Web of Science ®Google Scholar
• Jung L. K. L., Hara T., Fu S. M. Detection and functional studies of p60–65 (Tac antigen) on activated human B cells. J Exp Med. 1984; 160: 1597–1602
   PubMed Web of Science ®Google Scholar
• Herrmann F., Cannistra S. A., Levine H., Griffin J. D. Expression of interleukin 2 receptors and binding of interleukin 2 by gamma interferon‐induced leukemic and normal monocytic cells. J Exp Med. 1985; 162: 1111–1116
   PubMed Web of Science ®Google Scholar
• Birchenall‐Sparks M., Farrar W. L., Rennick D., Kilian P. L., Rusceti F. W. Regulation of expression of the interleukin‐2 receptor on hematopoietic cells by interleu‐kin‐3. Science 1986; 233: 455–458
   PubMed Web of Science ®Google Scholar
• Mntni T., Uchiyama T., Hori T., Itoh K., Uchino H., Ueda R. Elevated serum soluble interleukin‐2‐recep‐tor (Tac antigen) levels in chronic myelogenous leukemia patients with blastic crisis. Blood 1989; 74: 1052–1057
   PubMed Web of Science ®Google Scholar
• Michalevicz R., Campana D., Katz T. E., Janossy G., Hoffbrand A. V. Recombinant interleukin 2 and anti‐Tac influence the growth of enriched multipotent hematopoietic progenitors: Proposed hypothesis for different responses in early and late progenitors. Leuk Res. 1988; 12: 113–121
   PubMed Web of Science ®Google Scholar
• Tanaka J., Imamura M., Kasai M., Masauzi N., Watanahe M., Matsuura A., Morii K., Kiyama Y., Naohara T., Saito M., Higa T., Honke K., Gasa S., Sakurada K., Miyazaki T. Cytokine gene expression in peripheral blood mononuclear cells during graft‐versus‐host disease after allogeneic bone marrow transplantation. Br J Haema‐tol. 1993; 85: 558–565
   PubMed Web of Science ®Google Scholar
• Imamura M., Hashino S., Kobayashi H., Kobayashi S., Hirano S., Minagawa T., Tanaka J., Fujii Y., Kobayashi M., Kasai M., Sakurada K., Miyazaki T. Serum cytokine levels in bone marrow transplantation: Synergistic interaction of interleukin‐6, interferon‐γ, and tumor necrosis factor‐α in graft‐versus‐host disease. Bone marrow Transplant. 1994; 13: 745–751
   PubMed Web of Science ®Google Scholar
• Tanaka J., Imamura M., Kasai M., Hashino S., Kobayashi S., Noto S., Sakurada K., Asaka M. Cytokine network in peripheral blood mononuclear cells after allogeneic bone marrow transplantation. Transplant Proc. 1996; 28: 1746–1747
   PubMed Web of Science ®Google Scholar
• Tanaka J., Imamura M., Kasai M., Hashino S., Kobayashi S., Noto S., Higa T., Sakurada K., Asaka M. The important balance between cytokines derived from type 1 and type 2 helper T cells in the control of graft‐versus‐host disease. Bone Manow Transplant. 1997; 19: 571–576
   PubMed Web of Science ®Google Scholar
• Miyamoto T., Akashi K., Hayashi S., Gondo H., Murakawa M., Tanimoto K., Harada M., Niho Y. Serum concentration of the soluble interleukin‐2 receptor for monitoring acute graft‐versus‐host disease. Bone Marrow Transplant. 1996; 17: 185–190
   PubMed Web of Science ®Google Scholar
• Kobayashi S., Imamura M., Hashino S., Tanaka J., Asaka M. Clinical relevance of serum soluble interleukin‐2 receptor levels in acute and chronic graft‐versus‐host disease. Leuk Lymphoma. 1997; 28: 159–169
   PubMed Web of Science ®Google Scholar
• Khwaja A., Carver J., Jones H. M., Paterson D., Linch D. C. Expression and dynamic modulation of the human granulocyte colony‐stimulating factor receptor in immature and differentiated myeloid cells. Br J Haematol. 1993; 85: 254–259
   PubMed Web of Science ®Google Scholar
• Shieh J. H., Peterson R. H., Moore M. A. Modulation of granulocyte colony‐stimulating factor receptors on murine peritoneal exudate macrophages by tumor necrosis factor‐alpha. J Immunol. 1991; 146: 2648–2653
   PubMed Web of Science ®Google Scholar
• Bocchietto E., Guglielmetti A., Silvagno F., Taraboletti G., Pescarmona G. P., Mantovani A., Bussolino F. Proliferative and migratory responses of murine microvascu‐lar endothelial cells to granulocyte‐colony‐stimulating factor. J Cell Physiol. 1993; 155: 89–95
   PubMed Web of Science ®Google Scholar
• Imamura M., Fujimoto H., Hashino S., Fukuhara T., Kobayashi M., Sakurada K., Miyazaki T. In vivo administration of cytokine in allogeneic bone marrow chimeras. Immunobiol. 1990; 180: 441–457
   PubMed Web of Science ®Google Scholar
• Dreger P., Grelle K., Eckstein V., Suttorp M., Muller‐Ruchholtz W., Loffler M., Schmitz N. Granulocyte‐colony‐stimulating factor induces increased serum levels of soluble interleukin 2 receptors preceding engraftment in autologous bone marrow transplantation. Br J Haematol. 1993; 83: 7–13
   PubMed Web of Science ®Google Scholar
• Cuthbert R. J., Phillips G. L., Bamett M. J., Nantel S. H., Reece D. E., Shepherd J. D., Klingemann H. G. Anti‐interleukin‐2 receptor monoclonal antibody (BT 563) in the treatment of severe acute GVHD refractory to systemic corticosteroid therapy. Bone Marrow Transplant. 1992; 10: 451–455
   PubMed Web of Science ®Google Scholar
• Herbelin C., Stephan J. L., Donadieu J., Le Deist F., Raca‐dot E., Wijdenes J., Fisher A. Treatment of steroid‐resistant acute graft‐versus‐host disease with an anti‐IL‐2‐receptor monoclonal antibody (BT 563) in children who received T cell‐depleted, partially matched, related bone marrow transplants. Bone Marrow Transplant. 1994; 13: 563–569
   PubMed Web of Science ®Google Scholar
• Asano S., Masaoka T., Takaku F. Beneficial effect of recombinant human glycosylated granulocyte colony‐ stimulating factor in marrow‐transplanted patients: results of multicenter phase II‐III studies. Transplant Proc. 1991; 23: 1701–1703
   PubMed Web of Science ®Google Scholar
• Pan L., Delmonte J., Jr, Jalonen C. K., Ferrara J. L. M. Pretreatment of donor mice with granulocyte colony‐stimulating factor polarizes donor T lymphocytes toward Th2 cytokine production and reduces severity of experimental graft‐versus‐host disease. Blood 1995; 86: 4422–4429
   PubMed Web of Science ®Google Scholar
• Zeng D., Dejhakhsh‐Jones S., Strober S. Granulocyte colony‐stimulating factor reduces the capacity of blood mononuclear cells to induce graft‐versus‐host disease: Impact on blood progenitor cell transplantation. Blood 1997; 90: 453–463
   PubMed Web of Science ®Google Scholar
• Tanaka J., Mielcarek M., Torok‐Storb B. Impaired induction of the CD28‐responsive complex in granulocyte colony‐stimulating factor mobilized CD4 T cells. Blood 1998; 91: 347–352
   PubMed Web of Science ®Google Scholar
• Storek J., Gooley T., Siadak M., Bensinger W. I., Maloney D. G., Chauncey T. R., Flowers M., Sullivan K. M., Wither‐spoon R. P., Rowley S. D., Hansen J. A., Storb R., Appelbaum F. R. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft‐versus‐host disease. Blood 1997; 90: 4705–4709
   PubMed Web of Science ®Google Scholar